Do sulfonylureas primarily lower fasting glucose or post‑prandial glucose?

Sulfonylureas Control Both Fasting and Postprandial Glucose

Sulfonylureas primarily lower both fasting and postprandial glucose levels, with their predominant effect being on fasting glucose through sustained 24-hour insulin secretion stimulation. This differs from glinides (meglitinides), which specifically target postprandial glucose with minimal effect on fasting levels 1.

Mechanism and Glycemic Effects

Sulfonylureas work by stimulating insulin secretion from pancreatic β-cells throughout the day, resulting in:

• Fasting plasma glucose reduction: 3-5 mmol/L decrease 2
• Postprandial glucose reduction: Also significantly lowered 3, 2
• HbA1c reduction: 1.0-1.5% 1

The key distinction is that sulfonylureas enhance total daily insulin secretion, which addresses both fasting and postprandial hyperglycemia 4. This continuous insulin secretion effect means they work around the clock, not just at mealtimes.

Comparison with Other Agents

The evidence clearly differentiates sulfonylureas from meal-specific agents:

• Glinides (repaglinide, nateglinide): Reduce postprandial glucose by stimulating early-phase insulin secretion but have virtually no effect on fasting glucose 1, 3, 4
• Metformin: Primarily affects fasting glucose through reduced hepatic glucose output, with minimal effect on postprandial levels 3
• α-glucosidase inhibitors: Specifically target postprandial glucose with little fasting glucose effect 5, 3

Clinical Implications

When choosing sulfonylureas, understand that:

1. They address both glycemic components but are not meal-timed medications like glinides
2. Newer generation agents (gliclazide MR, glimepiride, glipizide) have lower hypoglycemia risk compared to older agents like chlorpropamide or glyburide 6
3. Hypoglycemia risk exists precisely because they provide continuous insulin secretion, not just postprandial coverage 6

Important Caveats

• The continuous insulin secretion that lowers fasting glucose also creates hypoglycemia risk, particularly in elderly patients and those with renal impairment 6, 7
• Greatest caution is needed in patients at high hypoglycemia risk: older adults, those with chronic kidney disease, and those combining sulfonylureas with insulin 6, 7
• For patients needing primarily postprandial control without fasting glucose lowering, glinides are the more appropriate insulin secretagogue choice 1, 4

The evidence from multiple guidelines consistently demonstrates that sulfonylureas are broad-spectrum glucose-lowering agents affecting both fasting and postprandial glucose, distinguishing them from the meal-specific action of glinides 6, 1, 3.